Denali Therapeutics Inc. (NASDAQ:DNLI) Gains Review Extension And Accelerates Launch Readiness
![]() |
A three-month FDA review extension slows the immediate approval timeline, while a robust cash position and concentrated R&D spending sustain late‑stage execution toward a potential product launch. |










